Tagista, tablets 8 mg 30 pcs

Tagiste has a histamine-like, microcirculatory improving effect.

Pharmacodynamics

Betahistine acts mainly on the histamine H1- and H3-receptors of the inner ear and vestibular nuclei of the CNS.

At the direct agonist effect on the H1-receptors of the inner ear vessels and also indirectly through the effect on the RH-receptors it improves microcirculation and capillary permeability and normalizes the endolymph pressure in the labyrinth and cochlea.

At the same time betahistine increases blood flow in the basilar artery. It has a pronounced central effect, being an inhibitor of NZ-receptor nuclei of the vestibular nerve.

Normalizes conduction in neurons of vestibular nuclei at brainstem level. Clinical manifestation of the above properties is reduction of the frequency and intensity of dizziness, decrease of tinnitus, improvement of hearing if it is reduced.

Pharmacokinetics

Absorbed rapidly, binding to plasma proteins is low. Time of reaching maximum concentration in blood plasma – 3 hours.

Extracted almost completely by the kidneys as a metabolite (2-pyridylacetic acid) within 24 hours.

The elimination half-life is 3 – 4 hours.

Indications

Meniere’s Disease, Cerebral Circulatory Disorders, Dizziness

• Treatment and prevention of vestibular vertigo of various origins;
• Treatment and prevention of vestibular vertigo of various origins
• Syndromes including vertigo and headache, tinnitus, progressive hearing loss, nausea and vomiting;
• Meniere’s disease or syndrome.

Active ingredient

Betahistine

Composition

1 tablet contains

The active ingredient:

Betahistine dihydrochloride 8.0 mg;

Excipients:

Microcrystalline cellulose – 54.75 mg,

Povidone (collidone 25) – 9.0 mg

Potato starch – 20.0 mg,

Citric acid – 2.0 mg,

Colloidal silica (aerosil), – 3.0 mg,

Talc – 2.8 mg,

Magnesium stearate – 0.45 mg.

.

How to take, the dosage

Overly, with meals.

Tablets 8 mg: 1-2 tablets 3 times a day.

Emprovement is usually seen early in therapy; stable therapeutic effect occurs after two weeks of treatment and may increase over several months of treatment.

The treatment is long. The length of treatment is determined individually.

Interaction

There are no known cases of interaction or incompatibility with other medicines.

Special Instructions

Betahistine has no sedative effect and does not affect the ability to drive or engage in activities requiring rapid psychomotor reactions

Synopsis

Tablets are almost white or white with a creamy tint, flat-cylindrical with a bevel and a rib.

Features

Absorbed rapidly, binding to plasma proteins is low.

Time to reach maximum concentration in blood plasma – 3 hours.

Almost completely eliminated by the kidneys as a metabolite (2-pyridylacetic acid) within 24 hours.

The elimination half-life is 3-4 hours.

Contraindications

• High sensitivity to any of the drug components;
• Age under 18 years (due to lack of data)
• Pregnancy and lactation (due to lack of data).

With caution

Gastric or duodenal ulcer (including anamnesis), pheochromocytoma, bronchial asthma.

These patients should be regularly monitored during treatment.

Side effects

• Gastrointestinal disorders,
• sensitivity reactions from the skin (rash, itching, urticaria),
• Quincke’s edema.

.

Overdose

Symptoms: nausea, vomiting, convulsions.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

.

Similarities

Betaserk, Vestibo, Betahistine, Betahistine NW, Tagista, Vertran